Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty

American Journal of Cardiology

Volumn 83, Issue 11, 1999, Pages 1569-1570

  Sundlof, Deborah W ^a   Rerkpattanapitat, Pairoj ^a   Wongpraparut, Nattawut ^a   Pathi, Padmavathi ^a   Kotler, Morris N ^a   Jacobs, Larry E ^a   Ledley, Gary S ^a   Yazdanfar, Shahriar ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; CREATINE KINASE; FIBRINOLYTIC AGENT; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0033153133     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00151-4     Document Type: Article

References (11)

1. Ryan T.J., Anderson J.L., Antman E.M., Braniff B.A., Brooks N.H., Califf R.M., Hilles L.D., Hiratzka L.F., Rapaport E., Riegal B.J., et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction a report of the ACC/AHA Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) . J Am Coll Cardiol. 28:1996;1328-1428.
2. Ellis S.G., Van de Werf F., Ribeiro- daSilva E., Topal E.J. Present status of rescue coronary angioplasty current polarization of opinion and randomized trials . J Am Coll Cardiol. 19:1992;681-686.
3. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., Terrin M.L. Thrombolysis in Myocardial Infarction (TIMI) trial. Phase 1 Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase . J Am Coll Cardiol. 11:1988;1-11.
4. Ohman E.M., Califf R.M., Topal E.J., Candela R., Abbottsmith C., Ellis S., Sigmon K.N., Kereiakes D., George B., Stack R. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 82:1990;781-791.
5. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
6. Eisenberg P.R., Sherman L.A., Tiefenbrunn A.J., Ludbrook P.A., Sobel B.D., Jaffe A.S. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Haemost. 57:1987;35-40.
7. Kleiman N.S., Ohman E.M., Califf R.M., George B.S., Kereiakes D., Aguirre F.V., Weisman H., Schaible T., Topol E.J. Profound inhibition of platelet aggregation with monoclonal antibody 7e3 fab after thrombolytic therapy results of the Thrombolysis And Angioplasty in Myocardial Infarction (TAMI) 8 pilot study . J Am Coll Cardiol. 22:1993;381-389.
8. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrelin in acute myocardial infarction. Circulation. 95:1997;846-854.
9. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI the PARADIGM trial . (abstr) Circulation. 94:(suppl I):1996;I-553.
10. Ferguson J.J. Meeting highlights of the 47th Annual scientific sessions of the American College of Cardiology. Circulation. 97:1998;2377-2381.
11. The comparative effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615.